The Department of Science and Technology (DOST) welcomed Monday, April 26, the decision of US-based drugmaker Moderna to apply for an emergency use authorization (EUA) of its coronavirus disease (COVID-19) vaccine in the Philippines.
DOST Secretary Fortunato “Boy” T. de la Peña and Undersecretary Rowena Cristina Guevara, chair of the Task Group on Vaccine Evaluation and Selection (TG-VES), cited Moderna’s filing of its EUA application before the Food and Drug Administration (FDA) on Monday, April 26.
"The more brands granted EUA by our FDA means we have more choices and bigger chances for vaccine availability,” de la Peña told the Manila Bulletin in a Viber message.
FDA Director General Eric Domingo announced that Moderna has filed its EUA application before the regulatory body on Monday, April 26.
https://mb.com.ph/2021/04/26/fda-moderna-applies-for-eua-of-its-covid-19-vaccine-in-ph/
"We have been expecting this for some time now,’ Guevara said.
When asked if Moderna’s use of mRNA technology platform will be considered by the FDA before granting EUA to Moderna, the TG-VES chief said, “There is enough documentation on mRNA platform so the FDA will be able to process this, just like the other EUA applications."
According to data from the Department of Health (DOH), Moderna vaccine uses an mRNA technology platform.
It has an efficacy rate of 94.1 percent against symptomatic COVID-19, while 100 percent “against severe COVID-19”, it showed.